Low sexual desire in women: causes, options, and questions
A useful evaluation starts with the person, not a product. The timing of the change, associated distress, medical history, medications, pain, and relationship context can all affect the next step.
Low desire and HSDD are not identical
Medical references distinguish ordinary variations in desire from hypoactive sexual desire disorder. The FDA label for bremelanotide describes acquired, generalized HSDD as low desire causing marked distress or interpersonal difficulty, without a better explanation such as a coexisting condition, relationship problem, or medication effect.
Possible contributors to discuss
- New or changed medications, including some antidepressants.
- Pain, vaginal dryness, hormonal changes, or other health conditions.
- Sleep, stress, mood, and mental health.
- Relationship context, communication, and sexual history.
- Menopause and other life-stage changes.
A clinician may review your history, recommend tests in some situations, or suggest a specialist. A website questionnaire cannot rule out every cause.
Treatment is not only medication
Mayo Clinic describes education, counseling, and sex or couples therapy as potential parts of care. Research on digital interventions is also developing. The appropriate option depends on the cause, the person’s goals, and any associated distress.
Understand FDA-approved and compounded options
Flibanserin and bremelanotide injection have specific FDA-approved uses for acquired, generalized HSDD in certain premenopausal women. They have labeled limitations and safety considerations. FDA approval of a specific product and formulation does not establish the safety or effectiveness of a different compounded formulation or combination.
Questions for an online consultation
- What possible causes should we review before treatment?
- Could counseling, medication review, or in-person evaluation be more appropriate?
- What evidence applies to this exact medication and formulation?
- What contraindications, interactions, and side effects apply to me?
- Who answers follow-up questions and how are side effects handled?
- What is the full cost and what happens if the clinician declines treatment?
Where Desira fits
Desira is Odelle’s compounded sublingual tablet containing bremelanotide and oxytocin. Odelle states that Desira-specific timing has not been established and that a licensed provider must review each patient before prescribing. It is not FDA-approved, and it should not be treated as interchangeable with Vyleesi or Addyi.
Frequently asked questions
Is occasional low desire the same as HSDD?
No. HSDD involves persistent low desire accompanied by marked distress or interpersonal difficulty, and it is not better explained by another medical or psychiatric condition, relationship problems, or a medication or substance.
What non-medication options can help?
Depending on the cause, a clinician may recommend education, counseling, sex therapy, couples counseling, or reviewing medications and health conditions. There is no single approach for everyone.
Which medications are FDA-approved for HSDD?
Flibanserin and bremelanotide injection have specific FDA-approved uses for acquired, generalized HSDD in certain premenopausal women. Their labels include limitations and safety information.
Is Desira FDA-approved?
No. Desira is a compounded sublingual tablet containing bremelanotide and oxytocin. Compounded products are not FDA-approved or reviewed by the FDA for safety, effectiveness, or quality.
Is Desira the same as Vyleesi?
No. Vyleesi is an FDA-approved bremelanotide injection with a specific indication and label. Desira is a compounded sublingual combination product. Evidence for one should not be assumed to establish evidence for the other.
Does Odelle guarantee a prescription for Desira?
No. A licensed provider reviews the health form and decides whether Desira is appropriate.
Sources
- FDA: Vyleesi prescribing information
- Mayo Clinic: Low sex drive in women, diagnosis and treatment
- CU Anschutz: HSDD in women
- JMIR: Digital health tool for low sexual desire in women
- FDA: Compounding and FDA questions and answers
Published and last reviewed for source accuracy: November 1, 2026. This page provides general information, not personal medical advice.